Table 1. Vascular risk factor profile of the study population.
| Variable | HOMA-IR Q1–Q3 (n=130) | HOMA-IR Q4 (n=43) | P1 |
|---|---|---|---|
| Age at baseline, median (IQR) | 66 (59–70) | 62 (56–68) | <0.05 |
| Male, n (%) | 69 (53.1) | 23 (53.5) | NS |
| BMI, median (IQR), kg/m2 | 26.8 (24.9–28.3) | 29.6 (28.1–31.1) | <0.01 |
| NIHSS score | 10 (7–15) | 16 (11–20) | <0.001 |
| Time from stroke onset to inclusion, h, median (IQR) | 4.5 (2.0–8.0) | 6.0 (2.5–10.5) | <0.05 |
| Time from stroke onset to blood collected, h, median (IQR) | 12.5 (9.5–17.5) | 15.0 (11.0–25.0) | <0.05 |
| Prior vascular risk factors, number (%) | |||
| Hypertension | 67 (51.5) | 33 (76.7) | <0.01 |
| Hypercholesterolemia | 43 (33.1) | 20 (46.5) | <0.05 |
| CVD | 28 (21.5) | 10 (23.3) | NS |
| Previous TIA | 20 (15.4) | 13 (30.2) | <0.01 |
| PVD | 11 (8.5) | 4 (9.3) | NS |
| Smoking | 26 (20.0) | 9 (20.9) | NS |
| Blood pressure, median (IQRs), mmHg | |||
| Systolic | 140 (132–148) | 145 (135–155) | <0.05 |
| Diastolic | 81 (77-87) | 86 (81–93) | <0.01 |
| Moderate-heavy physical activity, n (%) | 36 (27.7) | 5 (11.6) | <0.01 |
| Pre-stroke treatment, number (%) | |||
| Antiplatelet agents | 28 (21.5) | 9 (20.5) | NS |
| Statins | 17 (13.1) | 6 (14.0) | NS |
| Laboratory findings, median (IQR) | |||
| FBG, mmol/l | 5.15 (4.89–5.48) | 5.77 (5.38–6.03) | <0.001 |
| Hs-CRP, mg/dl | 0.50 (0.32–0.64) | 0.56 (0.38–0.77) | <0.01 |
| Triglycerides, mmol/l | 1.56 (1.32–1.79) | 1.89 (1.56–2.05) | <0.01 |
| Cholesterol level, mmol/l | |||
| HDL | 1.10 (0.95–1.25) | 0.94 (0.83–1.19) | <0.01 |
| LDL | 2.75 (2.55–3.07) | 2.80 (2.59–3.12) | NS |
Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; NS, No Significance.
1
P-value was assessed using Mann–Whitney U test or Chi-square test.